TON - June 2021 Vol 14, No 3

From The Editors June 2021
In the June issue of The Oncology Nurse-APN/PA (TON), we feature a selection of articles aimed at helping our readers stay informed on important issues relevant to nurses, navigators, and advanced practice providers as they care for patients with cancer. Read More ›

Nationwide Children’s Hospital in Columbus, OH, is one of the largest pediatric hospitals in the United States and is currently ranked as one of the top 10 children’s hospitals in the country by US News & World Report’s 2020-2021 “Best Children’s Hospitals Honor Roll” list. Read More ›

Gastrointestinal (GI) malignancies account for 26% of the global cancer incidence and 35% of all cancer-related deaths. Read More ›

The addition of the PI3K inhibitor copanlisib (Aliopa) to rituximab (Rituxan) reduced the risk for disease progression or death by 48% compared with rituximab alone in patients with relapsed indolent non-Hodgkin lymphoma (NHL) in the phase 3 CHRONOS-3 clinical trial. Read More ›

Despite improvements in the treatment of advanced ovarian cancer, less than half of newly diagnosed patients survive longer than 5 years, and relapse rates remain high. At the Society of Gynecologic Oncology (SGO) 2021 Virtual Annual Meeting on Women’s Cancer, experts presented updated results from 2 phase 3 clinical trials showing the benefit of the poly (ADP-ribose) polymerase (PARP) inhibitors olaparib (Lynparza) and niraparib (Zejula) as maintenance therapy in women with advanced or recurrent disease. Read More ›

Neutropenia is characterized by low levels of neutrophils, the white blood cells that fight infections. In general, the condition is defined as an absolute neutrophil count (ANC) <1500/μL. Read More ›

A small-molecule CD73 inhibitor (AB680) induced a 41% overall response rate (ORR) when combined with chemotherapy (with nab-paclitaxel and gemcitabine), plus the novel PD-1 inhibitor zimberelimab, as a first-line treatment for patients with metastatic pancreatic cancer according to results of the dose-escalation portion of the phase 1/1b ARC-8 study. Read More ›

Selpercatinib (Retevmo) demonstrated antitumor activity in RET fusion–positive tumors other than lung cancer and thyroid cancer, according to interim results from the phase 1/2 LIBRETTO-001 clinical trial. Read More ›

Researchers have identified 2 inherited pathogenic genetic variants in patients with pediatric neuroblastoma, according to results from a study presented at the 2021 virtual American Association for Cancer Research annual meeting. Read More ›

According to results from a large meta-analysis, breast cancer survivors of child-bearing age are less likely than the general population to get pregnant and face greater risk for certain complications, including preterm labor and cesarean section. Read More ›

Page 1 of 2

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: